Adagene (FRA:978) Retained Earnings: €-280.78 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:978 Adagene Inc FRA:978
42 GF Score
Price €2.86
GF Value €11.65
! 3 Warning Signs
View Full Analysis

What is Adagene Retained Earnings?

Adagene FRA:978 -4.67% 42 Retained Earnings is €-280.78 Mil as of Dec. 2025. GuruFocus rates FRA:978 with a GF Score™ of 42/100 and a GF Value™ of €11.65. The stock has 3 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Adagene's retained earnings for the quarter that ended in Dec. 2025 was €-280.78 Mil.

Adagene's quarterly retained earnings increased from Dec. 2024 (€-297.17 Mil) to Jun. 2025 (€-281.47 Mil) and increased from Jun. 2025 (€-281.47 Mil) to Dec. 2025 (€-280.78 Mil).

Adagene's annual retained earnings declined from Dec. 2023 (€-254.70 Mil) to Dec. 2024 (€-297.17 Mil) but then increased from Dec. 2024 (€-297.17 Mil) to Dec. 2025 (€-280.78 Mil).


Adagene  (FRA:978) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Adagene Retained Earnings Historical Data

* Premium members only.

The historical data trend for Adagene's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adagene Retained Earnings Chart

Adagene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial -158.27 -244.31 -254.70 -297.17 -280.78

Adagene Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -254.70 -273.84 -297.17 -281.47 -280.78
FRA:978
42GF Score
Adagene Inc FRA:978
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adagene Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-280.78 Mil mean?
Adagene (FRA:978) has a Retained Earnings of €-280.78 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Adagene and its competitors.
Is Adagene's Retained Earnings too high?
Adagene's current Retained Earnings is €-280.78 Mil. Overall, Adagene has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Adagene's Retained Earnings compare to RNAC and LYEL?
Adagene's Retained Earnings of €-280.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Adagene and its competitors. Adagene's current Retained Earnings is €-280.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adagene stock overvalued right now?
Adagene (FRA:978) has a current Retained Earnings of €-280.78 Mil. The stock's GF Value™ is €11.65, compared to a current price of €2.86 — trading 75.5% below its estimated fair value. The current Retained Earnings is €-280.78 Mil. Adagene's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Adagene (FRA:978), the current Retained Earnings is €-280.78 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adagene (FRA:978) Overvalued in 2026?

Based on GuruFocus' analysis, Adagene stock appears to be undervalued. The current stock price of €2.86 is trading 75.5% below its estimated GF Value™ of €11.65.

Key valuation signals for FRA:978:

  • Retained Earnings: €-280.78 Mil
  • GF Value™: €11.65 vs. price of €2.86 (75.5% below fair value)
  • GF Score™: 42/100 with 3 warning signs

No single metric tells the full story. See the FRA:978 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Adagene Business Description

Other Exchanges ADAG:USA
Address Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
42GF Score

Get the complete analysis for FRA:978

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.86
Price
€11.65
GF Value